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Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) are the 
primary eating disorders (EDs). The only psychopharmacological treatment options for EDs 
with approval in some countries include fluoxetine for BN and lisdexamfetamine for BED. 
Given the high comorbidity and genetic correlations with other psychiatric disorders, it seems 
possible that novel medications for these conditions might also be effective in EDs. 
The current scientific literature has increased our understanding of how medication could be 
beneficial for patients with EDs on a molecular, functional and behavioral level. On the basis 
of theoretical considerations about neurotransmitters, hormones and neural circuits, possible 
drug targets for the treatment of EDs may include signal molecules and receptors of the self-
regulatory system such as serotonin, norepinephrine and glutamate, the hedonic system 
including opioids, cannabinoids and dopamine and the hypothalamic homeostatic system 
including histamine, ghrelin, leptin, insulin, and glucagon-like peptide-1. 
The latest research points to an involvement of both the immune and the metabolic systems in 
the pathophysiology of EDs and highlights the importance of the microbiome. Therefore, the 
next few years may unveil drug targets for EDs not just outside of the brain, but possibly 





1.1. Historical preliminary remarks 
Despite decades of clinical experience and research in the field of eating disorders (EDs), the 
prognosis for patients with EDs is still poor. For example, a recent cohort study showed that 
only 30% of patients with anorexia nervosa (AN) have recovered after 9 years [1]. 
If we take a look at the broader history of psychiatry from the start of the 19th century 
onwards, asylum numbers increased steadily up to the 1950s despite big efforts of 
deinstitutionalization and the availability of psychological therapies. In 1950 the therapeutic 
effect of the first antipsychotic drug chlorpromazine was recognized [2]. This discovery led 
to a massive breakthrough in psychiatric therapy and to a drop of the residential psychiatric 
population in the United States of America (US) by 30% between 1955 and 1968 [3]. On top 
of that, chlorpromazine [2] and other new psychopharmacological drugs like the 
antidepressant imipramine [4, 5] allowed the mentally ill to live in their own homes and to 
obtain employment [3]. As those medications represented a massive achievement and helped 
with delusions, anxiety and low mood, they were also tried in patients with EDs, where these 
symptoms are highly prevalent [6, 7]. 
Because of anecdotal reports of success with antipsychotics, the use of first-generation 
antipsychotics to treat AN was investigated in open and uncontrolled, but also in randomized 
controlled trials (RCTs) in the 1970s and 1980s (for review see [7, 8]). Vandereycken [9] for 
example, reported a study using the antipsychotic sulpiride. In this RCT sulpiride was 
superior to placebo in terms of weight gain during the acute treatment period; however, it did 
not have any significantly beneficial effect on anorexic psychopathology such as anxiety and 
body image disturbances [9]. 
Regarding tricyclic antidepressants (TCAs), similar results were obtained from studies 
performed in the in the 1970s and 1980s [10, 11] (for review see [7, 8, 12]). Biederman et al. 
[10], for instance, reported a study comparing the effects of amitriptyline and placebo on 
weight gain and psychiatric symptomatology with no significant differences between the two 
groups except for more adverse effects in the amitriptyline group. Even though there were 
also few positive reports about the use of TCAs [13], the overall impression was that 
treatment with first-generation antipsychotics and TCAs could not be recommended [7] due 
to a lack of evidence and a high dropout rate in patients receiving these medications. Hence, 
these psychopharmacological agents did not gain general acceptance for the treatment of EDs 
at that time; and it seemed like patients with EDs could not benefit from the great 
breakthrough psychopharmacological therapies had achieved in other areas of psychiatry. 
Between the 1980s and today, the situation changed due to diagnostic and 
psychopharmacological advances. In terms of diagnostic categories, bulimia was included 
into the DSM-III in 1980 [14] after the description of “bulimia nervosa” by Gerald Russell 
[15]; and in 2013, DSM-5 introduced BED as s separate disorder [16]. Regarding new 
psychopharmacological developments, the selective serotonin reuptake inhibitor (SSRI) 
fluoxetine came into the market in 1986. It was tested in patients with BN yielding positive 
results [17] and approved by the US Food and Drug Administration (FDA) in 1987. Since 
then a large amount of evidence has been collected [18-22], fluoxetine is now the first-line 
psychopharmacological treatment for BN [23]. The psychopharmacological advances on the 
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basis of the introduction of SSRIs into the market are reflected by a Cochrane Review which 
revealed that patients treated with TCAs dropped out of RCTs more frequently than patients 
treated with placebo, but that the opposite was found for those treated with the SSRI 
fluoxetine, suggesting fluoxetine is a more acceptable treatment [24]. Additionally, another 
systematic Cochrane Review demonstrated that combination treatments using psychotherapy 
plus an antidepressant in bulimia nervosa were superior to single psychotherapy [25].  
In the 2000s and 2010s, the idea of treating EDs with antipsychotics was also revived, 
because second-generation antipsychotics became available. For example, an increasing 
amount of evidence has been gathered from RCTs [26-29] (for review see [30]) and clinical 
observations (for example [31]) showing that olanzapine may be helpful to treat symptoms of 
AN.  
On top of these pioneering diagnostic and therapeutic advances, there was significant 
progress in other research areas such as epidemiology and comorbidity research [32-40], 
genetics [41-51], research on neural circuits and neurotransmitters [52-83] and on hormonal 
appetite regulation [84-87]. The results obtained in these research fields of the last few 
decades led to a deeper understanding of the biology of EDs. 
1.2. Aim of this review 
In this review article, we summarize novel clinical and epidemiological data, outline genetic 
and neurobiological advances, and comment on possible future translational and personalized 
approaches. The most important aim of this article is to bring together the results of 
pharmacological research, brain imaging and RCTs to develop a hypothetical model of where 
drugs for EDs act in the brain (see Figure 1). We think that this hypothetical model 
summarizes decisive scientific findings related to the psychopharmacological treatment of 
EDs, helps to understand the bigger picture of how medications can influence the brain on a 
molecular and functional level, and thus may facilitate the scientific discussion and the 
communication between clinicians, patients and carers about this important clinical topic. 
As typical antipsychotics and TCA have not gained acceptance for the treatment of EDs, we 
don’t include these studies into the main reasoning of this paper, but refer to previous 
research articles and reviews.   
 
2. Eating Disorders 
2.1. Diagnostic considerations 
EDs are characterized by a persistent disrupted eating behavior which leads to changes in the 
dietary intake, impaired physical health and psychosocial problems. The Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5) currently recognizes three primary EDs: 
anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED) [16]. 
Additionally, the DSM-5 mentions avoidant/restrictive food intake disorder (ARFID; an 
eating disturbance manifested by a restrictive eating pattern with persistent failure to meet 
appropriate nutritional needs), pica (the consumption of non-food) and rumination disorder 
(regurgitation and re-chewing food) [16]. For these latter three disorders there are no 
psychopharmacological RCTs reported in the literature as yet. 
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Within the EDs, clinical features can change over time, a proportion of patients with AN 
transition to BN and BED, and additionally, people with EDs, specifically BED can develop 
obesity. Overall, about one-half of patients with BED are obese [88] with obesity prevalence 
increasing over time from about 20% at baseline to about 40% five years later [89]. There are 
also a large number of patients with obesity who report binge eating with percentages ranging 
from 12% to 78% according to the degree of severity [90-93]. In individuals who seek weight 
control treatment the prevalence of BED is about 30% [93]. Obesity, however, is not 
considered an ED in DSM-5, even though there was a proposal to do so [94]. 
2.2. Anorexia nervosa  
The prevalence of AN is approximately 1-4% among women, but lower in men with a sex 
ratio of men to women of about 1:10 [32, 33]. The peak incidence is at an age between 14 
and 17 years [34]. AN is frequently associated with depressive disorder [36], obsessive 
compulsive disorder (OCD) and autism spectrum disorder [37]. The course is often chronic 
and it can lead to persistent disability [95]. A recent longitudinal cohort study showed that 
about 30% of patients with AN have recovered after 9 years and about 60% after 22 years [1]. 
The main criteria for the diagnosis are a significantly low body weight in the context of age, 
sex, and physical health, intense fear of weight gain and disturbed body perception [16]. The 
dietary deficit is often accompanied by significant physical health issues such as growth 
retardation, osteopenia, amenorrhoea and renal insufficiency, but also changes in laboratory 
parameters, cardiac arrhythmia and disturbances of the thyroid function [96]. The most 
common causes of death in patients with AN are sudden cardiac death associated with 
ventricular arrhythmias and suicide [97-99]. An overview on the prevalence, diagnostic 
criteria, and frequent psychiatric comorbidities for each ED is provided in Table 1. 
2.3. Bulimia nervosa 
BN occurs in 1-2% of women with a sex ratio of men to women of about 1:10 which is 
comparable to AN. The peak age is between 20 and 30 years [33, 34]. BN is often associated 
with affective disorders [36], impulse control disorders, attention deficit/hyperactivity 
disorder (ADHD), drug dependence, anxiety disorders, dissociative disorders, and the mental 
consequences of childhood trauma [36, 38, 39]. The main criteria for the diagnosis of BN are 
recurrent binges (the consumption of an unusually large amount of food within a short time 
interval associated with loss of control) associated with compensatory behaviors such as 
vomiting, excessive physical activity or fasting at least once a week for three months and 
excessive preoccupation with shape and weight [16]. 
2.4. Binge Eating Disorder 
BED is the most prevalent EDs and can lead to reduced social and emotional functioning, 
quality of life, productivity and health impairments. Many patients are unaware that it is a 
recognized form of EDs and present for treatment for weight-related issues or comorbid 
medical and psychiatric conditions such as affective and anxiety disorders [35, 40]. BED is 
about twice as frequent as BN (between 2 and 5% of the population) with the proportion of 
women being about 60% among patients with BED [33]. BED is characterized by the 
intermittent consumption of large quantities of food (binge eating) at least once a week for 
three months without the use of the extreme compensatory strategies such as purging used in 
BN [16].  
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2.5. The spectrum of eating disorders 
Given that transitions between diagnostic categories are common, some theorists have 
proposed dimensional models of EDs or - in other words - a spectrum of disordered eating. 
This view is supported by the fact that there are many overlapping risk factors and symptoms 
[94, 100-104]. 
2.6. Preliminary remarks regarding psychopharmacological treatment 
Psychological therapies are currently the main treatment strategies for AN, BN and the BED. 
Only few psychopharmacological agents have been approved for EDs in some countries. We 
have already highlighted the high comorbidity at a symptom or syndrome level with affective 
disorders, anxiety disorders, autism, OCD, ADHD, and substance-related disorders [36-42]. 
Therefore it stands to reason that medication approved to treat these highly comorbid 
conditions might also be useful in the treatment of EDs. Moreover, comorbidities might help 
to define specific subgroups of patients suffering from EDs and to develop individually 
tailored drug therapies to treat the ED. Even though the current literature doesn’t allow such 
far reaching conclusions, comorbidities might help specify the disturbed neural circuits 
underlying the ED in an individual patient, as we will explain below. 
 
3. Biological findings in patients with eating disorders 
3.1. Genetics 
The familial nature of AN has been well established; the first-degree relatives of individuals 
with AN have approximately a tenfold greater lifetime risk of falling ill with an ED than 
relatives of unaffected individuals [41-44]. 
However, family studies are unable to determine the extent to which the observed familial 
aggregation is due to genetic or environmental factors. To determine the genetic risk, twin 
studies have been performed, which have yielded a high heritability of 50-60%; for example, 
a large twin study performed by Bulik et al. [41] led to a heritability estimation for AN of 
56%, with the remaining variance attributable to shared environment and unique 
environment.  
The genetic liability to AN is, like other complex disorders, thought to consist of many 
genetic variations of small effect identified by genome wide association study (GWAS) 
techniques [45-47]. In a GWAS reported by Duncan et al., however, the authors identified 
one genome-wide significant locus on chromosome 12 in a region harboring a previously 
reported type 1 diabetes and autoimmune disorder locus [47]. Genetic studies using state-of-
the-art technologies in BN or BED are limited [48], and to our knowledge no large GWAS 
have been performed in BN and BED yet. 
The so-called LD score regression (LDSR) has been used to estimate the shared genetics 
(genetic covariance from GWAS studies) between disorders. This has revealed significant 
positive genetic correlations between AN and OCD, schizophrenia and neuroticism [47, 49, 
50]. Additionally, there are genetic correlations with somatic and metabolic features 
including specific insulin, glucose, and lipid phenotypes and a significant negative correlation 
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between the body mass index (BMI) [47, 49, 50]. 
BMI related genes such as the polymorphism of the fat mass and obesity-associated (FTO) 
gene have also been found to be associated with BED [51]. Thus disorders with loss of 
control over eating seem to share a similar genetic profile to obesity. 
These genetic findings suggest that EDs like AN and BED may not only be psychiatric 
disorders or – in other words – disorders of the brain, but also metabolic or immune 
disorders. Moreover, the mentioned novel genetic data could mean that there are different 
subtypes of EDs, for example a psychological, a metabolic and an immune subtype of AN. 
This development could change the way we see and treat EDs, because immunological and 
metabolic messenger molecules like cytokines and hormones may play important roles as 
drug targets for EDs in the future.  
3.2. Neural circuits and neurotransmitters 
Appetite control includes a complex integration of several neural circuits including those 
related to (1) self- and social regulation, learning and memory, (2) hedonic aspects associated 
with the desire to eat and pleasure during food consumption and satiation, and (3) the 
homeostatic regulation which integrates peripheral signals of food consumption and energy 
stores with central systems of appetite control [52-58]. These neural circuits are both 
anatomical and functional entities. On the basis of the current literature we propose a model 
in which we allocate certain brain functions, anatomic structures, their input and signal 
molecules, associated comorbidities and psychopharmacological agents to these three 
systems, the self-regulatory, the hedonic and the homeostatic system [52]. However, this is 
only an attempt to classify comorbidities and medications according to the putatively most 
relevant neural circuits for EDs. We are aware that this model includes several 
simplifications, but it helps to understand the role of the most important neural circuits and 
their signal molecules in EDs in keeping with the latest research. For further information 
regarding these three systems see Table 2.  
The self-regulatory system which is mainly located in the prefrontal cortex embeds eating 
into the social context, forges individual values and self-regulatory control by incorporating 
social, cultural and environmental factors through learning for which the neurotransmitters 
serotonin, serotonin (5-HT), norepinephrine (NE), acetylcholine (ACh) and dopamine (DA) 
play an important role [52-60]. These neurotransmitters have been shown to be involved in 
mood disorders, OCD, anxiety disorders, personality disorders, neuroticism and 
schizophrenia. Therefore, medications that play a role in these disorders like antidepressants, 
antipsychotics, glutamatergic agents and anti-dementia drugs could be considered to 
influence this system and therefore to be potentially useful in the treatment against EDs as we 
will explain in detail later. We are not aware of any scientific literature on cognitive 
enhancers for the treatment of EDs. However, one single anti-dementia drug has been 
theoretically considered [105], The self-regulatory system seems to play a decisive role in the 
pathophysiology of BN, as a functional magnetic resonance imaging studies found abnormal 
patterns of activation in frontal systems which are important for the regulatory control of food 
intake [106, 107]. These divergent activation patterns may be responsible for the inability of 
patients with BN to control conflicting desires to consume fattening foods on the one hand 
and to avoid weight gain on the other hand [106]. 
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Neural reward dysfunction in the hedonic system may underpin dysfunctional eating behavior 
in AN, BN and BED with anorexia nervosa associated with too little striving for reward and 
binge eating too much [55-64, 108]. Prefrontal areas, particularly the orbitofrontal cortex 
(OFC) and corticostriatal circuits including the nucleus accumbens play an important role in 
reward processes [64-67]. A recently proposed bio-psycho-social model suggests that in AN 
there is a hypersensitivity to food stimuli, whereas there may be a desensitization to food 
stimuli specific in BN, BED and obesity) [66, 67]. Being sated or hungry, or being 
underweight or overweight is associated with heightened or reduced brain reward response in 
the insula, the subcortical ventral striatum, and the prefrontal cortex [67]. A number of 
different neural messenger molecules such as endogenous opiates and cannabinoids and 
dopamine are involved in the in the reward system [68-72]. Opiate agonists, inverse agonists 
and antagonists such as naltrexone, naloxone, nalmefene and GSK1521498 have all been 
found to influence eating behavior and the hedonic value of foods [68-72]. The hedonic 
system is additionally modulated by peripheral hormones involved in appetite regulation such 
as ghrelin and leptin [73, 74]. Several studies have provided evidence for altered patterns of 
hedonic system activity associated with reward processing in acutely ill patients with AN and 
recovered individuals [109]. Patients with AN show less hedonic response to eating, but 
consider behaviors like self-starvation – which are considered aversive and punishing in 
healthy people – more rewarding than eating [109]. On the contrary, subjects with BED show 
higher scores of hedonic eating compared to healthy controls [110]. 
The hypothalamus plays a central role in the homeostatic system regulating of food intake and 
body weight. It integrates signals about the nutritional state and food supply from the 
periphery and modulates food intake and energy consumption [75, 76]. An important 
orexigenic signal leading to hunger and food intake is ghrelin which is produced in the 
stomach [77]. Anorexigenic signals from the body periphery include glucose, the enterocyte 
hormone glucagon-like peptide-1 (GLP-1) [78], the pancreatic hormone insulin and the fatty 
tissue hormone leptin [76]. In the hypothalamus, the arcuate nucleus, the paraventricular 
nucleus and the lateral hypothalamus are of particular relevance for weight regulation [76, 
79]. The arcuate nucleus integrates the incoming humoral signals of GLP-1, insulin, leptin, 
ghrelin and other hormones and energy carriers such as glucose and converts them into 
neuronal signals. Orexigenic hypothalamic signalling molecules are NPY and AgRP which 
lead to an increase in appetite, while α-MSH as well as cocaine and amphetamine regulated 
transcript (CART) are anorexic signals which lead to a feeling of satiety [76]. α-MSH is 
produced by the so-called pro-opiomelanocortin (POMC) neurons. [80]. In acute episodes of 
AN, for example, ghrelin has been found to be overexpressed, and leptin reduced as would be 
expected in starvation [96]. However, plasma levels of NPY (part of the orexigenic system) 
are anomalously low [96]. Abnormalities within the hormonal regulation of the homeostatic 
system have also been reported for BN [111] and BED [112]. 
Within the arcuate nucleus, orexigenic factors increase hypothalamic adenosine 
monophosphate-activated protein kinase (AMPK) activity which is an intracellular appetite 
signal leading to food intake [79, 80]. This homeostatic system is modulated by 
neurotransmitters of the hedonic system (cannabinoids, endogenous opioids and dopamine) 
as well as signaling molecules of the self-regulatory system like serotonin, norepinephrine, 
glutamate, and acetylcholine [81-83]. Histamine plays a central role in the homeostatic 
system itself, as we will explain in the next paragraph. Figure 1 depicts a simplified 
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overview of the interplay of these appetite-regulating molecules within the three systems, the 
homeostatic system, the self-regulatory and the hedonic system.  
The atypical antipsychotic olanzapine, an antagonist at serotonin and dopamine receptors, is 
of interest as a treatment option for AN [26-31, 113]. It has been reported to lead to weight 
gain in patients with schizophrenia [114] on the basis of its high affinity towards the 
histaminergic H1 receptor and its antihistaminergic action [115]. The antihistaminergic 
effects of olanzapine at the H1 receptor leads to an increase of the hypothalamic AMPK 
activity. Therefore, the antihistaminergic effect of olanzapine could be beneficial in the 
treatment of an ED like AN, where weight gain is intended. It has to be mentioned though 
that neurotransmitters and hormones which belong to the homeostatic system like insulin, 
leptin and ghrelin play important roles in food reward [73-76, 84, 85] which is an example 
how the three systems – the self-regulatory, the hedonic and the homeostatic system – 
influence each other and should therefore not be considered as separate from each other. 
3.3. Hormones 
Hormones like sex steroids also influence eating behaviour significantly. Human 
epidemiological and experimental animal studies have shown that, for example, oestrogens 
display a key role in the control of food intake and energy balance [87]. Furthermore, the lack 
of oestrogens causes impaired bone health in AN [116]. Another hormone which could be 
relevant in the development of EDs is the neuropeptide hormone oxytocin which has been 
shown to inhibit food intake and to increase energy expenditure in animals [117, 118]. It is 
released into systemic circulation in situations of psychosocial interaction, and has been 
shown to be involved in mechanisms of social bonding and social recognition [117, 118], 
areas where patients with AN show specific difficulties [119], and to be a possible mediator 
of SSRI-induced antidepressant effects [120]. 
 
4. Psychopharmacologic advances in anorexia nervosa 
A primary goal of RCTs to test medication in AN is the restoration of body weight or the 
stabilization of body weight after weight restoration. However, even though professionals and 
carers usually agree upon this treatment goal, a recent survey among AN patients and carers 
reveals that people with anorexia nervosa themselves want medication to help with anxiety 
and sleep problems [121], but doubt that psychopharmacological drugs can help with AN. 
This divergence in aims may account for poor take up and adherence [8, 30,] in 
pharmacological studies which has impeded developments in the field.  
Currently discussed psychopharmacological agents to treat for AN include atypical 
antipsychotics, the cannabinoid receptor (CB) agonist dronabiol and D-cycloserine [30]. A 
recent systematic review to summarize evidence from research on psychopharmacological 
options for adult patients with AN [8], however, came to the conclusion that the body of 
evidence for the efficacy of pharmacotherapy in AN was unsatisfactory, because the quality 
of observations was questionable, and sample size was often small. Nevertheless we will 




According to the mentioned current review to identify recent developments in the 
pharmacotherapy of eating disorders [30] and a recent meta-analysis [113], olanzapine is the 
most promising drug for patients with AN, because with regard to weight gain it was superior 
to placebo in four published RCTs [26-29], and in a not yet published but recently completed 
large, multisite RCT in patients with anorexia nervosa performed by Attia et al. [30]. In these 
studies, body weight gain was the major outcome measure. As olanzapine impacts 
serotonergic, dopaminergic and histaminergic neurotransmission, it could have impact on the 
self-regulatory, the hedonic and the homeostatic system. Through its antihistaminergic 
activity, olanzapine may also help patients with their anxiety [122] and sleep problems [123]. 
Previous studies [26-29] initiated olanzapine treatment at 2.5 mg/d and increased this dose 
slowly to 5 mg or 10 mg/d. This dosage is within the British National Formulary (BNF) 
limits [124], but at the lower end. As BNF cites caution for people with a slower metabolism 
and female patients, we recommend a slow up-titration schedule (2.5 mg/d increments each 
week up to a maximum of 10 mg/d), and the same down-titration increment at the end of 
treatment to improve patient safety.  
A few case reports suggest that aripiprazole - a partial dopamine agonist – may also be 
effective in the treatment of AN [125-127]. In a chart review of 75 patients with AN who 
received either olanzapine or aripiprazole, aripiprazole showed the greatest effectiveness in 
reducing eating-related preoccupations and rituals with a large effect size [128]. In the 
literature [125-127], relatively small doses were used. For example, in a case series published 
by Trunko et al. [125] patients received aripiprazole doses of between 5 and 15 mg/d. 
4.2. Dronabinol (cannabinoid receptor agonist): Dronabinol is a synthetic form of delta-9-
tetrahydrocannabinol (THC) acting on CB1 and CB2 [129]. It is available for the treatment of 
cachexia in tumour and HIV infected patients [130]. A small study (n=25) found that patient 
with AN who were treated with dronabinol showed an greater weight gain compared to 
placebo [131]. 
4.3. D-cycloserine (NMDA receptor agonist): D-cycloserine is a glutamatergic partial agonist 
at the glycine/D-serine site on the (N-methyl-D-aspartate) NMDA receptor, which is a 
subtype of glutamate receptors [132]. In a recently published trial with 36 patients with AN in 
which participants were randomly assigned to receive exposure therapy plus D-cycloserine or 
placebo, participants in the D-cycloserine group showed a significantly greater increase in 
BMI than those in the placebo group. D-cycloserine participants gained 3 pounds relative to 
0.5 pounds in the placebo group [133]. However, from this study, it can only be concluded 
that D-cycloserine improves the results of exposure therapy for AN, but not that it would lead 
to weight gain by itself in this patient group. Therefore, it may be one of the drugs which 
could rather be recommended to sustain normal weight after weight restoration or to enhance 
the effects of psychotherapy.  
These preliminary proof-of-concept studies suggest that olanzapine [26-29], aripiprazole 
[126-128] or dronabinol [131] may have promise (see Figure 1). However, for the moment 
any use of medication for AN itself would be considered off-label use, although medications 




5. Psychopharmacologic advances in bulimia nervosa 
In contrast to AN, the clinical use of medications in the treatment of BN has been well 
established [12, 30], and the SSRI fluoxetine has long been approved for the treatment of BN. 
RCTs usually aim to reduce binge and purge behaviour as main outcome parameter. As 
systematic reviews and guidelines have already summarized the results of RCTs in BN for 
antidepressants, antiepileptics, lithium and other drugs [12, 23], we will mainly focus on 
fluoxetine and topiramate, because these drugs appear as the treatment options supported by 
the most evidence. 
5.1. Serotonergic antidepressants  
The serotonergic agent fluoxetine which also influences NPY and POMC neurons in the 
hypothalamus [134] has a strong evidence for acute and maintenance treatment [17-22]. 
Fluoxetine should be started at a dose of 20 mg/d and increased to a dose of 60 mg/d. 60 
mg/d is the dose evaluated in both acute and recurrent prophylaxis with high evidence of 
clinical efficacy and a good benefit-risk profile. The dose of 60 mg/d is more effective than 
lower doses [23, 124, 135]. The positive effect on the number of binges seems to be 
independent of its antidepressant effect. Therapy length of two years is recommended [135].  
5.2. Topiramate (glutamatergic agent)  
The anti-epileptic drug topiramate interacts with voltage-gated calcium channels and thereby 
modulates glutamate levels and inhibits kainate-mediated conductance at glutamate receptors 
of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate type [136, 
137]. Therefore, we consider topiramate a glutamatergic agent. Additionally, it increases 
leptin, insulin and -MSH production [138]. It has been shown to be effective at reducing 
binge eating and self-induced vomiting in BN and is well-tolerated, in several RCTs. For 
example, in  studies published by Hoopes et al. and Hedges et al. [139, 140] topiramate led to 
signiﬁcantly greater reductions than placebo in the number of binge/purge days, in body 
dissatisfaction and drive for thinness. Abstinence rates from binge-eating and purging were 
23% for topiramate and 6% for placebo. Topiramate was associated with signiﬁcant 
reductions in anxiety, and participants on topiramate lost signiﬁcantly more weight than the 
placebo group, who tended to gain weight [139, 140]. Important side effects were tiredness as 
well as cognitive and mnestic disturbances. Topiramate is currently under scrutiny at the 
FDA for approval for binging and purging behaviour in BN and BED in a fixed combination 
with the stimulant phentermine. Topiramate treatment should start at 12.5 or 25 mg/d and 
increased very slowly to between 75 and 200 mg/d [124, 135] to avoid cognitive and mnestic 
side effects. Positive effects on binges and self-induced vomiting have been found in several 
RCTs. However, it is still not approved for the treatment of BN and therefore its use in BN is 
off-label. 
5.3. Others 
The serotonergic drug ondansetron showed a positive effect in several RCTs such as an RCT 
performed by Faris et al. [141], but cannot be recommended as an off-label indication for BN 
due to the risk of a dose-dependent prolongation of the QTc interval [142]. Naltrexone an 
antagonists at the μ-opioid receptor, the κ-opioid receptor and the δ-opioid receptor [143] has 
shown inconsistent results in BN, and the studies performed so far have low statistical power 
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[23]. In two small open trials, bulimic symptoms decreased significantly under treatment with 
naltrexone [144, 145]. Naltrexone, could represent a future psychopharmacological advance, 
if appropriately designed large studies will replicate the reported positive effects. 
 
6. Psychopharmacologic advances in binge eating disorder  
As BED is a relatively novel diagnosis [16], the number of RCTs testing 
psychopharmacological approaches for BED is limited. So far, main outcome criteria have 
been a reduction of binges and body weight [146-148]. 
6.1. Stimulants 
Lisdexamfetamine (LDX) is a prodrug of amphetamine which influences the hedonic system 
and also up-regulates CART expression in animal models [149, 150]. It was already approved 
for treatment of children and adults with ADHD. LDX is the only drug approved by the FDA 
for the treatment of moderate to severe BED in adults. However, it is only approved in the 
US; its use in other countries is still off-label. The approval was based on three studies which 
found LDX superior to placebo for reducing binge eating days, obsessive-compulsive binge 
eating symptoms, and body weight, and for inducing 4-week binge eating cessation rates 
[146-148]. The approval of LDX by the FDA in 2015, the same year as BED was 
acknowledged as an independent diagnosis in the DSM-5 [16], definitely represents a major 
advance in the psychopharmacological treatment of eating disorders. In a recent safety and 
tolerability trial, there was a four weeks initial titration dose which started at 30 mg/d LDX; 
the target and maintenance doses were between 50 and 70 mg LDX given over 48 weeks 
[151]. This approach is in keeping with the previous literature about LDX in patients with 
BED [146-148]. 
6.2. Others 
Drugs used for obesity may also reduce weight in BED as there is a significant overlap 
between both diagnoses [88-94]. Therefore, we would like to briefly mention these drugs as 
well, even though they are not yet tested for BED but only for obesity. Liraglutide is an 
analogue of the anorexigenic bowel hormone GLP-1 which binds to the GLP-1 receptors in 
the hypothalamus. It has been shown to lead to significant weight loss in obese patients and 
to an improvement regarding the various health consequences of obesity in a number of 
RCTs [152-157]. Two RCTs with naltrexone plus bupropion showed superior weight 
outcomes to placebo in patients with obesity with no adverse effects [158, 159]. This 
combination is thought to lead to weight loss by modulation of opioid, dopamine and 
norepinephrine signaling in both the self-regulatory and the reward system. Further new 
pharmacological approaches for obesity include the norepinephrine reuptake inhibitor 
reboxetine [160], the monoamine reuptake inhibitor tesofesin [161], the CB1 receptor 
antagonist taranabant [162], the peptide YY3-36 [163] which is a product of enteroendocrine 
cells, the pancreatic and lipase inhibitor cetilistat [164]. From preclinical and healthy studies, 
there is also evidence for the efficacy of intranasal insulin to reduce appetite and food intake 
[165]. Furthermore, there is already sufficient evidence from RCTs for the beneficial clinical 
effect of the serotonin receptor agonist lorcaserin [166] and the combination of the stimulant 





7.1. Psychopharmacological advances in EDs  
In AN, the reports of weight gain under the treatment with olanzapine [26-29], aripiprazole 
[125-128] or dronabinol [131] can be considered as psychopharmacological advances. As 
topiramate [139, 140] led to reductions in the number of binge/purge days, in body 
dissatisfaction and drive for thinness, it seems to be a promising novel development in BN. 
The approval of LDX for BED after convincing positive RCTs [146-148, 151] definitely 
represents a major advance in the psychopharmacological treatment of eating disorders. 
Apart from RCTs, there has also progress been made with regard to the understanding of 
where and how medication for EDs may work on a molecular level and thus influence 
important neural circuits. The results of these non-clinical studies encouraged us to formulate 
a comprehensive pharmacodynamic model which includes as major players signal molecules 
and receptors of the self-regulatory system such as serotonin, norepinephrine, acetylcholine 
and glutamate, of the hedonic system including opioids, cannabinoids and dopamine and of 
the hypothalamic homeostatic system including histamine, ghrelin, leptin, insulin, glucagon-
like peptide-1 (see Figure 1). Even though this model represents a simplification of study 
results, we hope that it helps to see the bigger picture of how psychopharmacological 
medication may be able to influence the brain for the benefit of patients with EDs. 
7.2. Critical remarks 
As already stated by several meta-analyses, systematic and narrative reviews [7, 8, 12, 23, 24, 
30] the majority of studies for drug treatment in EDs are small, and the study design across 
the studies is heterogeneous. We tried to draw conclusions about the most important drugs 
discussed in our article on the basis of meta-analysis and systematic reviews. However, for 
some promising medications like aripiprazole or dronabinol, there are no such articles 
available. Additionally, EDs are complex phenotypes with a variety of psychological and 
physical symptoms within one diagnostic category. In this article, however, we only resorted 
to the treatment of the whole disorder. Thus, we did not go into detail with regard to specific 
symptoms like ED-specific cognitions, hyperactivity or non-occurrence of menstruation. 
These are symptoms that could also be targeted pharmacologically. For example, current 
reports suggest the potential of leptin to treat hypothalamic amenorrhea in female patients 
[171] or anorexia based activity in rats [172]. Moreover, in order to focus on the attempt to 
classify medication according to their primary target location, we have given little attention to 
adverse effects.  
Drug treatment is set within the context of a wider treatment plan including psychotherapy, 
family therapy, diet counselling, occupational therapy and physiotherapy. However, space 
was too limited reflect on the interaction of these psychological interventions and drug 
treatment.  
Throughout our article, we focused more on problematic energy intake and eating behavior in 
EDs than on energy expenditure which is also regulated within the central nervous system 
and could therefore be tackled using psychopharmacological agents. Furthermore, peripheral 
molecular structures like the sirtuins which regulate cellular metabolism and mitochondrial 
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function might also be important for weight regulation [173].  
Our article is lacking a comprehensive synopsis of neuroendocrine findings which would 
potentially help to identify potential drug targets particularly in AN - e.g. low gonadotropin 
levels, high ghrelin levels and low leptin levels. For a compilation of these changes in 
laboratory parameters from our perspective, we recommend reading our previous article [96]. 
7.3. Future perspectives 
A more individualized approach based on biomarkers or neuropsychiatric findings could 
improve efficacy, effectiveness and adherence in psychopharmacological treatment for EDs. 
We have already highlighted the high comorbidity at a symptom as well as syndrome level 
with affective disorders such as depression, anxiety disorders, autism, OCD, ADHD, and 
substance-related disorders [36-40] and the positive genetic correlations between AN and 
OCD, schizophrenia and neuroticism [49, 50]. Therefore, approved treatment for these 
epidemiologically as well as biologically related disorders could be considered for EDs as 
well. Broadly speaking, current and future drugs used in other psychiatric disorders could be 
used in related EDs as well. Examples are LDX, essentially a long-acting D-amphetamine 
which is approved for the treatment of patients with ADHD, or fluoxetine which is an SSRI 
that has been used as a psychopharmacological drug for depression and OCD. We further 
assume that considering the associated disturbances in the underlying neural circuits might 
lead to a deeper understanding of the similarities between these disorders and EDs and 
therefore fertilize novel psychopharmacological approaches or improved combinations of 
psychotherapy and pharmacotherapy.   
 
8. Expert Commentary 
Current treatment outcomes for all EDs are poor. Outpatient interventions usually fail to 
achieve weight restoration in the vast majority of AN patients [174], only about 30% of 
patients with AN have recovered after 9 years [1] and patients with BED remain obese. 
Therefore, there is an urgent need for novel treatment options.  
One approach would be to look at comorbidities such as depression, anxiety, ADHD, OCD 
and schizophrenia. These comorbidities might give a hint about the underlying disturbed 
neural circuits. For example, a patient with BN, OCD symptoms and depression may most 
likely profit from an SSRI like fluoxetine, because there might be a serotonin-related 
disturbance in the self-regulatory system which leads to three different symptom patterns. 
This thought about comorbidities could also have relevance for future RCTs. For example, 
patients with AN and delusional symptoms might rather profit from an antipsychotic, and 
patients with AN and OCD might more likely improve during treatment with a serotonergic 
antidepressant. Therefore, to look at the comorbidities might help to create subtypes of 
patients, and to treat them in a more individualized way. It may well be that the low success 
rate in RCTs is due to the heterogeneity of patients, and that a more individualized approach 
would be more effective.  
Other novel approaches could be drugs which improve social relationships or learning to 
enhance the effects of psychotherapy for EDs. In this respect, we would like to refer again to 
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oxytocin [117-120] and D-cycloserine [133]. 
In view of future advancements in the pharmacotherapy of EDs, it may be useful to think 
about how medications could influence and treat psychopathological features, symptoms, 
emotional states and specific behaviors associated with EDs instead of treating comorbidities 
or the ED as a whole. Those emotional states and behaviors could relate to anxiety, anger, 
low self-esteem, self-criticism, asceticism, problems of social-emotional functioning, and 
suicidal and self-injurious behaviors. Psychopharmacological agents targeting specific 
psychopathological features, ways of behavior and emotional states should therefore be 
considered when planning future RCTs in patients with EDs. At this point, it is worth 
mentioning that patients and carers particularly like this approach of using medications to 
tackle specific symptoms such as anxiety [121].  
However, one main concern from our clinical experience is that many patients with AN 
refuse drug treatment, because they are afraid of weight gain. Therefore, compliance and 
adherence remain key problems for the treatment of EDs and require a high level of clinical 
expertise. In future research, the inclusion of Patient Reported Outcome Measures (PROMs) 
and Patient Reported Experience Measures (PREMs) into the outcome criteria for RCTs in 
EDs should be considered in order to make the participation in RCTs more attractive for 
patients with EDs [121]. PROMs and PREMs have already been developed within the 
National Health Service (NHS) of the United Kingdom (UK) for certain elective surgery 
procedures [175], but not yet for the psychopharmacological treatment of AN. If the main 
outcome criteria of an RCT were to include PROMs and PREMs regarding, for example, 
anxiety in addition to BMI changes, the RCT would be of benefit from a patients’ perspective 
and may improve the willingness to participate in the RCT [121]. 
 
9. Five-year view 
The latest genetic findings suggest that EDs may not only be seen as psychiatric, but also as 
metabolic or immune disorders, and that there may be different subtypes of EDs like a 
psychological, a metabolic and an immune subtype of each ED. In five years’ time we may 
be able to postulate those biologically distinct subtypes of EDs. 
Genetic research has linked EDs with disorders of the immune system [47]. These results are 
supported by anomalies in the cytokines system reported in patients with EDs [96, 176, 177]. 
Messenger molecules of the immune system may be promising future drug targets for EDs as 
they are significantly involved in appetite regulation [96, 178, 179]. The immunological 
perspective may also become interesting when taking into account the gastrointestinal 
microbiome and its interactions with diet, inflammation, and epigenetic alterations. Probiotics 
and bioactive nutrients have been shown to alter this microbiome as well as immune and 
brain function [180] and could therefore have therapeutic potential to influence appetite 
regulation and ED psychopathology [181]. Future genetic research in EDs may not only take 
human genes, epigenetics and gene expression, but also the genes of bacteria, fungi and other 
species living in the human body into account. Therefore, we assume that the next few years 
will unveil drug targets for EDs not just outside of the brain, but possibly even outside of our 




10. Key issues 
 The only approved psychopharmacological treatment options for EDs to date include 
fluoxetine for BN and lisdexamfetamine for BED. 
 Evidence derived from RCTs suggests that olanzapine may be helpful to treat 
symptoms of AN. 
 Given the high comorbidity with other psychiatric disorders, novel medications for 
these conditions might also be effective in EDs. 
 Currently discussed psychopharmacological medications for EDs influence three 
important neural circuits of the brain: the self-regulatory system, the hedonic system 
and the hypothalamic homeostatic system. 
 Drug targets for the treatment of EDs include molecules of the serotonin, 
norepinephrine, dopamine, histamine, glutamate, opioid and cannabinoid system as 
well as the hormones ghrelin, leptin, insulin and GLP-1. 
 Genetic research suggests that EDs should not only be perceived as disorders of the 
brain, but also as immune or metabolic disorders. Therefore, future pharmacological 
agents for EDs may primarily influence the immune system or metabolic processes of 
the body. 
 The microbiome seems to be an additional promising future drug target. 
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Table 1: Prevalence, decisive diagnostic criteria and frequent psychiatric comorbidities. 
Abbreviations: Obsessive-compulsive disorder (OCD), attention deficit/hyperactivity 
disorder (ADHD). For further details see text. 
Eating 
disorder  




 1-4% among 
women 
 Sex ratio men/ 
women: 1/10 
 Significantly low body weight  
 Intense fear of weight gain  
 Disturbed body perception 
 Depressive disorder 
 OCD 




 1-2% among 
women 
 Sex ratio: 1/10 
 Recurrent binges  
 Compensatory behaviors 
 Self-evaluation unduly 
influenced by body shape and 
weight 
 Affective and 
anxiety disorders 






 Childhood Trauma 
Binge eating 
disorder  
 3% of the 
population 
 Sex ratio 1/3 
 Binge eating 
 No extreme compensatory 
strategies 
 Affective disorders 





Table 2. Brain systems involved in the pathophysiology of EDs. This table attempts to 
categorize brain functions, anatomical structures and signal molecules in a simplified way, 
but in keeping with the current literature – according to the three arguably most relevant 
neural circuits: the self-regulatory, the hedonic and the homeostatic system. Abbreviations: 
Serotonin (5-HT), norepinephrine (NE), acetylcholine (ACh), dopamine (DA), neuropeptide 
Y (NPY), agouti-related peptide (AgRP), melanocyte-stimulating hormone (α-MSH), cocaine 
and amphetamine regulated transcript (CART), glucagon-like peptide-1 (GLP-1). For further 
details see text. 
Brain System Self-regulatory 
system 
Hedonic system Homeostatic system 
Functions  Embedding eating 
into social context  
 Individual values 
 Self-regulatory 
control 
 Desire to eat 
 Pleasure during 
food consumption 









 Prefrontal cortex  Prefrontal cortex 
 Basal ganglia 
 Thalamus 
 Hypothalamus 
Input  Social and cultural 
factors 
 Environment 
 Sensory organs 
 Hippocampus 






 Hedonic system 




















Figure 1: Schematic and simplified depiction of the interplay of the hedonic system, the self-
regulatory system, the homeostatic system, the body periphery and the molecular target 
location of selected promising medications to treat EDs. The potential indication is given in 
brackets. Abbreviations: Anorexia nervosa (AN), bulimia nervosa (BN), binge eating 
disorder (BED), opioids (Op), cannabinoids (CB), dopamine (DA), serotonin (5-HT), 
norepinephrine (NE), acetylcholine (ACh), glutamate (Glu), neuropeptide Y (NPY), agouti-
related peptide (AgRP), melanocyte-stimulating hormone (α-MSH), cocaine and 
amphetamine regulated transcript (CART), glucagon-like peptide-1 (GLP-1). For further 
details see text. 
 
 
 
 
